Democratic Republic of the Congo

Population 2017: 81 million

### Tuberculosis profile

#### Estimates of TB burden*, 2017

<table>
<thead>
<tr>
<th>Category</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>49 (29–74)</td>
<td>60 (35–90)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>7.5 (3.5–13)</td>
<td>9.2 (4.3–16)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>262 (169–374)</td>
<td>322 (208–460)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>20 (13–29)</td>
<td>25 (16–35)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>7.5 (3.3–13)</td>
<td>9.2 (4–17)</td>
</tr>
</tbody>
</table>

#### Estimated TB incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Gender</th>
<th>0-14 years</th>
<th>&gt; 14 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>16 (14–17)</td>
<td>84 (65–102)</td>
<td>99 (76–123)</td>
</tr>
<tr>
<td>Males</td>
<td>17 (16–19)</td>
<td>145 (103–187)</td>
<td>162 (112–212)</td>
</tr>
<tr>
<td>Total</td>
<td>33 (28–37)</td>
<td>229 (145–313)</td>
<td>262 (169–374)</td>
</tr>
</tbody>
</table>

#### TB case notifications, 2017

- Total cases notified: 151,832
- Total new and relapse: 150,085
- % tested with rapid diagnostics at time of diagnosis: 64%
- % with known HIV status: 83%
- % bacteriologically confirmed among pulmonary: 80%

#### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2017: 57% (40–89)
- TB case fatality ratio (estimated mortality/estimated incidence), 2017: 0.22 (0.11–0.35)

#### TB/HIV care in new and relapse TB patients, 2017

- Patients with known HIV-status who are HIV-positive: 9,688 (10%)
- on antiretroviral therapy: 7,982 (82%)

#### Drug-resistant TB care, 2017

- Estimated MDR/RR-TB cases among notified pulmonary TB cases: 3,400 (2,000–4,900)
- Estimated % of TB cases with MDR/RR-TB: 2.2% (1–3.5) 9.5% (8.8–10)
- % notified tested for rifampicin resistance: 3% 57% 10,543
- MDR/RR-TB cases tested for resistance to second-line drugs: 147
- Laboratory-confirmed cases: MDR/RR-TB: 893, XDR-TB: 19
- Patients started on treatment ****: MDR/RR-TB: 839, XDR-TB: 15

#### Treatment success rate and cohort size

- New and relapse cases registered in 2016: 89% 127,503
- Previously treated cases, excluding relapse, registered in 2016: 60% 769
- HIV-positive TB cases registered in 2016: 90% 463
- XDR-TB cases started on second-line treatment in 2015: 10% 21

#### TB preventive treatment, 2017

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 15% (14–17)
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment:

#### TB financing, 2018

- National TB budget (US$ millions): 74
- Funding source: 2% domestic, 48% international, 49% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2018-11-02

Data: www.who.int/tb/data